-
New indications for gastric cancer approved by Mercadon Pembrolizumab in China
On June 25th, Merck announced that its PD-1 inhibitor, Pembrolizumab (trade name: Koreda®), has been approved by the National Medical Products Administration (NMPA) of China for first-line treatm ...- suisuiblue
- 2024-6-25
- サポート
- に反対
- 返信
- コレクション
-
New indications for gastric cancer approved by Mercadon Pembrolizumab in China
On June 25, MSD China WeChat official account announced that its PD-1 inhibitor Pabolizumab (trade name: Kereida®) had been approved by the National Drug Administration (NMPA) of China to combine ...